Melanoma

EAY191 (ComboMATCH) **If biopsy needed, TBD at MBMC**

Molecular Analysis for Combination Therapy Choice

---

ALLIANCE A212102 **AT MBMC ONLY** **As of 8/1/23 the following Healthy Control Cohorts are Open (all others are Closed as of 2/22/23): Non-White Male Participants Age 60 or More Without Cancer Diagnosis and Non-White Male Participants Under Age 60 Without Cancer Diagnosis**

Blinded Reference Set For Multicancer Early Detection Blood Tests

---

URCC 19075 **MBMC ONLY**

Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)

---

A091903

A Randomized Phase II Trial of Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Musocal Melanoma

---

NCI 10323

Cancer Moonshot Biobank Research Protocol

---

S2013: I-CHECKIT

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

---

EA6192 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

---

A151804

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

---

URCC 18007

Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue

---

ECOG-ACRIN EA6141 (NCT02339571)

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

---